Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Scilex Holding Company ( (SCLX) ).
On December 16, 2025, Scilex Holding Company‘s subsidiary SCLX Stock Acquisition JV LLC entered into a loan agreement with The St. James Bank & Trust Company Ltd., securing a loan facility of up to $100 million. The agreement involves pledging a significant portion of Scilex’s common stock as security and includes terms relating to interest rates, maturity dates, and default conditions, emphasizing the structured obligations and associated risks for Scilex’s financial operations.
The most recent analyst rating on (SCLX) stock is a Buy with a $770.00 price target. To see the full list of analyst forecasts on Scilex Holding Company stock, see the SCLX Stock Forecast page.
More about Scilex Holding Company
Scilex Holding Company operates in the pharmaceutical industry, focusing on the development and commercialization of novel, non-opioid therapies for pain management and other innovative treatments. The company aims to address unmet needs in the healthcare market through its specialized product portfolio.
Average Trading Volume: 189,300
Technical Sentiment Signal: Sell
Current Market Cap: $119.5M
See more data about SCLX stock on TipRanks’ Stock Analysis page.